

From: NRESCCommittee.EastMidlands-Nottingham2@nhs.net <noreply@harp.org.uk>

Sent: 20 January 2020 11:51

To: Nikola Sprigg <mszns4@exmail.nottingham.ac.uk>; Nikola Sprigg <mszns4@exmail.nottingham.ac.uk>; sponsor@nottingham.ac.uk

Subject: IRAS Project ID 233744. HRA Approval for the Amendment

Dear Dr Sprigg,

IRAS Project ID:	233744
Short Study Title:	Desmopressin for treatment of stroke patients on antiplatelet therapy
Amendment No./Sponsor Ref:	MA/04/19
Amendment Date:	13 January 2020
Amendment Type:	Non Substantial CTIMP

I am pleased to confirm **HRA and HCRW Approval** for the above referenced amendment. You should implement this amendment at NHS organisations in England and Wales, in line with the conditions outlined in your categorisation email.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: <http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/>.

Please contact hra.amendments@nhs.net for any queries relating to the assessment of this amendment.

Kind Regards

Beverley Mashegede

Health Research Authority

Ground Floor | Skipton House | 80 London Road | London | SE1 6LH

E. hra.amendments@nhs.net

W. www.hra.nhs.uk

Sign up to receive our newsletter [HRA Latest](#).